2. Disease Areas
  3. Metabolic or Endocrine Disease
  4. Mineral Metabolism
  5. Hypercalcemia

Hypercalcemia

Hypercalcemia is a common clinical condition characterized by elevated serum calcium levels, typically above the normal range of 2.1–2.6 mmol/L, resulting from excessive calcium entry into the extracellular fluid or impaired renal excretion. The most frequent causes are primary hyperparathyroidism and malignancy-associated hypercalcemia, together accounting for over 90% of cases. These conditions often lead to increased bone resorption or impaired kidney function. Early symptoms are frequently mild and nonspecific, including constipation, nausea, vomiting, abdominal pain, and loss of appetite, while more severe manifestations—such as confusion, depression, weakness, kidney stones, bone pain, and abnormal heart rhythms—may occur with higher or rapidly rising calcium levels. In extreme cases, hypercalcemia can lead to life-threatening complications like cardiac arrest. Although many patients with mild hypercalcemia remain asymptomatic, it remains a significant metabolic disorder requiring timely diagnosis and management to prevent long-term complications such as bone demineralization and renal impairment.

References:

Hypercalcemia (4):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P4821
    pTH (1-34) amide (human) 83139-29-1 99.78%
    PTH (1-34) amide human is a type 1 PTH/PTHrP receptor agonist. PTH (1-34) amide human activates adenylate cyclase and phospholipase C pathways, thereby mediating mineral ion homeostasis and bone metabolism regulation. PTH (1-34) amide human increases serum calcium, decreases serum phosphorus, regulates renal excretion, while inducing the inhibition of endogenous PTH (1-84) and the increase of 1,25-dihydroxyvitamin D2 and bone resorption. PTH (1-34) amide human stimulates phosphatidylcholine hydrolysis via phospholipase D mediation, and its hypercalcemic effect is inhibited by human PTH-(7-84). PTH (1-34) amide human can be used in the research of diseases related to humoral hypercalcemia of malignancy.
    pTH (1-34) amide (human)
  • HY-N0805A
    Alisol B 18649-93-9 99.57%
    Alisol B is a triterpene with diverse biological activities. Alisol B binds human soluble epoxide hydrolase (sEH) with a Ki of 5.97 μM and reduces sEH activity. Alisol B inhibits RANKL-induced JNK phosphorylation, NFATc1 and c-Fos expression, osteoclast formation, mature osteoclast pit-forming and actin ring activity, and SERCA pump activity. Alisol B induces calcium mobilization, CaMKK-AMPK-mTOR pathway activation, autophagic flux, autophagosome formation, G1 phase cell cycle arrest, endoplasmic reticulum stress, unfolded protein responses, and cancer cell apoptosis. Alisol B can be used for the research of hypercalcemia, osteoporosis, rheumatoid arthritis, periodontitis, acute kidney injury, and breast cancer.
    Alisol B
  • HY-P4827
    pTH (1-84) (dog) 521986-14-1
    pTH (1-84) dog is a biologically active full-length canine parathyroid hormone, as well as an agonist of PTHR. pTH (1-84) dog can be detected by the "intact" PTH (W-PTH) assay, thus effectively distinguishing inactive C-terminal fragments. In terms of metabolic regulation, it rapidly and persistently stimulates hepatic glucose release, hepatic alanine uptake, and alanine-based gluconeogenesis in conscious fasted dogs, and causes a secondary increase in circulating canine insulin levels due to enhanced glucose release. However, high doses of pTH (1-84) (dog) may induce adverse reactions such as hypercalcemia in dogs. Based on the above characteristics, this hormone can be widely used in studies related to canine hyperadrenocorticism (HAC).
    pTH (1-84) (dog)
  • HY-16498
    Tigapotide 848084-83-3
    Tigapotide (PCK-3145) is a synthetic 15-mer peptide derived from prostate-secretory protein, and acts as an antineoplastic agent. Tigapotide inhibits tumor growth, experimental bone metastasis, and malignancy-associated hypocalcemia. Tigapotide induces apoptosis in prostate cancer cells and tumors, and suppresses the growth of prostate cancer cells. Tigapotide inhibits the production of parathyroid hormone-related protein (PTHrP) in tumors and plasma. Tigapotide reduces plasma calcium levels in hypercalcemic tumor-bearing rats. Tigapotide is applicable for the research of prostate cancer and malignancy-associated hypercalcemia.
    Tigapotide